[11]Kurozumi S, Padilla M, Kurosumi M, et al. HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients. Breast Cancer Res Treat. 2016;158(1):99-111. [12]van Mackelenbergh MT, Loibl S, Untch ...
[3]Von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012 May 20;30(15):1796-804. [4]Kang YJ, Han W, Park S, et al. Outcome followi...
HER2-positive breast cancer: incidence, prognosis, and treatment options. Am J Cancer. 2003; 2 :169–179.Estevez LG, Seidman AD. HER2-positive breast cancer: incidence, prognosis, and treatment options. Am J Cancer. 2003;2:169-179.
[3]Von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012 May 20...
[17]Kim MH, Kim GM, Kim JH, Kim JY, Park HS, Park S, et al.. Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older. Breast Canc...
Interestingly, Czerniecki et al. showed anti-HER2 CD4+Th1 immunity to be a relevant component of HER2+therapy, as loss of CD4+Th1 responses correlated with poor prognosis and treatment responses15. The administration of a class II HER2 peptide-pulsed Type I polarized DC1 vaccine was shown to ...
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. PURPOSE: To explore the prognostic and/or predictive value of human epidermal growth factor receptor 2 (HER2) pathway-related...
[5] Horisawa, N. et al. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer 29, 234–241. [6] Tan, R. S. Y. C. et al. HER2 expression, copy number variatio...
In summary, our results provided evidence for the prognostic and predictive value of BCSCs in HER2-positive primary breast cancer. Expression of CD44+/CD24 was found to be an independent negative indicator for prognosis and a predictive marker for trastuzumab response in HER2-postive primary breast...
[10]Hanna WM,et al.HER2 in situ hybridization in breast cancer:clinical implications of polysomy 17 and genetic heterogeneity.Mod Pathol 2014;27:4–18. [11]Kurozumi S,et al.HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative...